Dyadic International (DYAI) Competitors $1.06 +0.01 (+0.95%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DYAI vs. CSBR, KPTI, CKPT, RANI, ANVS, TELO, PDSB, ELYM, INMB, and DERMShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Champions Oncology (CSBR), Karyopharm Therapeutics (KPTI), Checkpoint Therapeutics (CKPT), Rani Therapeutics (RANI), Annovis Bio (ANVS), Telomir Pharmaceuticals (TELO), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), INmune Bio (INMB), and Journey Medical (DERM). These companies are all part of the "medical" sector. Dyadic International vs. Champions Oncology Karyopharm Therapeutics Checkpoint Therapeutics Rani Therapeutics Annovis Bio Telomir Pharmaceuticals PDS Biotechnology Eliem Therapeutics INmune Bio Journey Medical Champions Oncology (NASDAQ:CSBR) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation. Is CSBR or DYAI more profitable? Champions Oncology has a net margin of -6.58% compared to Dyadic International's net margin of -428.86%. Dyadic International's return on equity of -145.95% beat Champions Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Champions Oncology-6.58% -850.72% -12.80% Dyadic International -428.86%-145.95%-75.92% Which has more risk & volatility, CSBR or DYAI? Champions Oncology has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Do insiders and institutionals hold more shares of CSBR or DYAI? 41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 28.8% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend CSBR or DYAI? Champions Oncology presently has a consensus price target of $6.00, indicating a potential upside of 53.45%. Dyadic International has a consensus price target of $6.00, indicating a potential upside of 466.04%. Given Dyadic International's higher probable upside, analysts plainly believe Dyadic International is more favorable than Champions Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, CSBR or DYAI? Dyadic International has lower revenue, but higher earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChampions Oncology$50.15M1.06-$7.28M-$0.26-15.04Dyadic International$1.80M17.18-$6.80M-$0.28-3.79 Does the MarketBeat Community prefer CSBR or DYAI? Dyadic International received 10 more outperform votes than Champions Oncology when rated by MarketBeat users. Likewise, 64.26% of users gave Dyadic International an outperform vote while only 60.24% of users gave Champions Oncology an outperform vote. CompanyUnderperformOutperformChampions OncologyOutperform Votes15060.24% Underperform Votes9939.76% Dyadic InternationalOutperform Votes16064.26% Underperform Votes8935.74% Does the media favor CSBR or DYAI? In the previous week, Champions Oncology had 1 more articles in the media than Dyadic International. MarketBeat recorded 1 mentions for Champions Oncology and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 1.89 beat Champions Oncology's score of 1.04 indicating that Dyadic International is being referred to more favorably in the news media. Company Overall Sentiment Champions Oncology Positive Dyadic International Very Positive SummaryDyadic International beats Champions Oncology on 9 of the 16 factors compared between the two stocks. Ad Timothy SykesAlgo Trading Is Here 🔥One trade alert each day backed by powerful technology, yours free. For $0 you can get access to one daily stock picked directly from StocksToTrade’s algo-powered system.>> Click here to sign up & get the next 🔥alert sent directly to your phone << Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.99M$3.16B$5.36B$8.41BDividend YieldN/A1.77%5.22%4.20%P/E Ratio-3.7916.48131.9317.57Price / Sales17.18343.231,440.1578.36Price / CashN/A139.6939.0633.56Price / Book5.303.904.744.57Net Income-$6.80M-$40.42M$115.43M$225.42M7 Day Performance-4.33%-0.16%-0.86%-0.61%1 Month Performance1.92%3.45%3.61%1.50%1 Year Performance-34.57%32.76%38.90%32.94% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International2.5552 of 5 stars$1.06+1.0%$6.00+466.0%-34.8%$30.99M$1.80M-3.797Positive NewsGap UpCSBRChampions Oncology4.197 of 5 stars$3.91+3.2%$6.00+53.5%-32.8%$53.14M$50.15M-15.04143Short Interest ↓Positive NewsGap UpKPTIKaryopharm Therapeutics4.3941 of 5 stars$0.99+17.9%$5.00+405.2%+2.5%$123.35M$145.67M-0.84380Upcoming EarningsShort Interest ↓News CoverageGap UpHigh Trading VolumeCKPTCheckpoint Therapeutics3.5528 of 5 stars$3.44-5.0%$12.00+248.8%+91.5%$122.76M$78,000.00-1.8110Short Interest ↑High Trading VolumeRANIRani Therapeutics3.2116 of 5 stars$2.29-1.3%$11.71+411.5%+18.4%$122.30M$2.72M-1.94110Positive NewsANVSAnnovis Bio2.1401 of 5 stars$9.30-2.6%$32.17+245.9%+17.7%$121.40MN/A-1.823Short Interest ↑TELOTelomir PharmaceuticalsN/A$4.06-7.9%N/AN/A$120.22MN/A0.001Positive NewsPDSBPDS Biotechnology1.0554 of 5 stars$3.19-0.6%$14.25+346.7%-23.5%$117.46MN/A-2.6120ELYMEliem TherapeuticsN/A$3.92-3.0%N/A+51.4%$116.63MN/A-7.4020INMBINmune Bio2.477 of 5 stars$5.85-1.7%$20.00+241.9%-12.0%$115.60M$85,000.00-2.8410Short Interest ↑News CoverageDERMJourney Medical3.7373 of 5 stars$5.75+0.5%$9.38+63.0%N/A$115.08M$77.68M-287.5090Upcoming EarningsShort Interest ↓ Related Companies and Tools Related Companies Champions Oncology Alternatives Karyopharm Therapeutics Alternatives Checkpoint Therapeutics Alternatives Rani Therapeutics Alternatives Annovis Bio Alternatives Telomir Pharmaceuticals Alternatives PDS Biotechnology Alternatives Eliem Therapeutics Alternatives INmune Bio Alternatives Journey Medical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DYAI) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.